ProKidney (PROK) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed ProKidney (PROK) over the past year, gaining 8.1% versus a loss of 52.5%. Over five years, TECX leads with a -57.7% price change compared with -89.5% for PROK. ProKidney is the larger company by market cap ($415.2 million vs $405.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | TECX |
|---|---|---|
| Share price | $1.04 | $20.73 |
| Market cap | $415.21M | $405.26M |
| 1-day change | -1.89% | -1.47% |
| YTD return | -53.57% | -0.62% |
| 1-year return | -52.51% | +8.08% |
| 5-year return | -89.49% | -57.66% |
| EPS (TTM) | $-0.61 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $893.00K | — |
| Revenue growth (YoY) | +1075.00% | — |
| Net income (latest FY) | $-68.99M | $-74.15M |
| Operating margin | -18477.83% | — |
| Net margin | -7725.20% | — |
| 52-week high | $2.65 | $39.53 |
| 52-week low | $0.87 | $16.77 |
| Distance from 52-week high | -60.75% | -47.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +525.00% | +242.50% |
| Average volume | 1.44M | 212.16K |
| Shares outstanding | 209.63M | 19.55M |
| Employees | 231 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed PROK by 60.6 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
PROK vs TECX FAQ
Which is bigger, ProKidney or Tectonic Therapeutic?
ProKidney (PROK) is larger, with a market capitalization of $415.21M compared with $405.26M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, PROK or TECX?
TECX returned +8.08% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.